NOVEN ANNOUNCES 2007 EARNINGS RELEASE DATE |
BackMiami, FL, March
6, 2008 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced
its 2007 earnings release date.
On March 13th, before the U.S. market
opens, Noven is scheduled to issue a press release announcing its financial
results for the quarter and year ended December 31, 2007. At 8:30 a.m.
Eastern Time the same day, a conference call with management will be
broadcast live via the Internet at www.noven.com, and thereafter a
rebroadcast will be accessible at the same site for at least two weeks.
A taped replay of the call will be available beginning March 13th through
March 15th by calling 877-660-6853 (from within the U.S.) or 201-612-7415
(from outside the U.S.) and entering account number 286 and conference
ID number 275402.
About Noven
Noven Pharmaceuticals, Inc., headquartered
in Miami, Florida, is a specialty pharmaceutical company engaged in
the research, development, manufacture, marketing and sale of prescription
pharmaceutical products. Noven’s leading transdermal products
utilize its proprietary DOT Matrix® drug delivery technology and
include Vivelle-Dot® (estradiol transdermal system), the most prescribed
estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal
system), the first and only patch approved for the treatment of ADHD.
Oral products currently offered through Noven’s psychiatry/CNS
marketing and sales organization consist of Pexeva® (paroxetine
mesylate) and Lithobid® (lithium carbonate). Developmental products
include Stavzor™ (delayed release valproic acid capsule) and
Mesafem™ (low-dose paroxetine mesylate), a non-hormonal product
for vasomotor symptoms. See www.noven.com for additional information.
Contact:
|
Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.